Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Up 6.6%

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) rose 6.6% on Thursday . The company traded as high as $26.99 and last traded at $26.86. Approximately 135,382 shares were traded during trading, a decline of 68% from the average daily volume of 424,195 shares. The stock had previously closed at $25.20.

Analyst Upgrades and Downgrades

Several equities analysts have commented on KNSA shares. Wedbush increased their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday. Evercore ISI lifted their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. JPMorgan Chase & Co. upped their price target on shares of Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, May 3rd. They set an “overweight” rating and a $34.00 price target on the stock. Four research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.00.

Kiniksa Pharmaceuticals Stock Up 7.1 %

The firm has a market cap of $1.92 billion, a P/E ratio of 244.20 and a beta of 0.38. The business’s 50 day moving average is $19.72 and its two-hundred day moving average is $19.37.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.83% and a negative net margin of 3.10%. The company had revenue of $108.30 million for the quarter, compared to the consensus estimate of $90.60 million. During the same period in the previous year, the business earned ($0.02) EPS. The firm’s revenue was up 51.5% compared to the same quarter last year. Equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.1 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Lazard Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals in the first quarter valued at $71,000. China Universal Asset Management Co. Ltd. boosted its holdings in Kiniksa Pharmaceuticals by 349.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock worth $72,000 after acquiring an additional 3,186 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Kiniksa Pharmaceuticals in the fourth quarter worth approximately $213,000. Bayesian Capital Management LP acquired a new stake in Kiniksa Pharmaceuticals in the first quarter valued at approximately $222,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Kiniksa Pharmaceuticals by 45.0% during the fourth quarter. Victory Capital Management Inc. now owns 14,653 shares of the company’s stock valued at $257,000 after acquiring an additional 4,547 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.